Exploiting proteases for cancer theranostic through molecular imaging and drug delivery

Int J Pharm. 2020 Sep 25:587:119712. doi: 10.1016/j.ijpharm.2020.119712. Epub 2020 Jul 31.

Abstract

The measurement of biological processes at a molecular and cellular level serves as a basis for molecular imaging. As compared with traditional imaging approaches, molecular imaging functions to probe molecular anomalies that are the basis of a disease rather than the evaluation of end results of these molecular changes. Proteases play central role in tumor invasion, angiogenesis and metastasis thus can be exploited as a target for imaging probes in early diagnosis and treatment of tumors. Molecular imaging of protease has undergone tremendous breakthroughs in the field of diagnosis. It allows the clinicians not only to see the tumor location but also provides an insight into the expression and activity of different types of markers associated with the tumor microenvironment. These imaging techniques are expected to have a huge impact on early cancer detection and personalized cancer treatment. Effective development of protease imaging probes with the highest in vivo biocompatibility, stability and most appropriate pharmacokinetics for clinical translation will upsurge the success level of early cancer detection and treatment.

Keywords: Imaging; Nanomaterial; Protease; Theranostic; Treatment; Tumor.

Publication types

  • Review

MeSH terms

  • Humans
  • Molecular Imaging
  • Neoplasms* / diagnostic imaging
  • Neoplasms* / drug therapy
  • Peptide Hydrolases
  • Pharmaceutical Preparations*
  • Precision Medicine
  • Theranostic Nanomedicine
  • Tumor Microenvironment

Substances

  • Pharmaceutical Preparations
  • Peptide Hydrolases